Scale-up Expertise Leverage Paragon Bioservices’ strong focus on viral vector scale-up and production to position as a partner for customers seeking scalable AAV and lentiviral vector manufacturing, potentially expanding services into early-stage to late-stage programs.

Cell Therapy Footprint Highlight Catalent Cell & Gene Therapy’s integrated autologous and allogeneic cell therapy development and manufacturing capabilities to target sponsors pursuing end-to-end cell therapy solutions, including CAR-T programs.

Global Manufacturing Network Emphasize access to large-scale clinical and commercial manufacturing facilities across the U.S. and Europe to appeal to sponsors needing regional scalability, fill-finish, and packaging capabilities.

Financial Growth Signals Revenue range indicates mid-market biotech services potential; target mid-to-large biotechs and emerging gene therapy companies seeking credible, scalable CDMO partners with a track record in viral vectors.

Competitive Positioning Position Paragon within a competitive landscape of established CDMOs by underscoring specialized viral vector capabilities, robust technical stack, and integration with a broad technology ecosystem to win deals from similar peers.